-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
Introduction to the Gouty Arthritis (GA) model of InnoModels Biotechnology
Author:
InnoModels
Release time:
2024-08-07
Gouty Arthritis (GA) is an inflammatory disease caused by the deposition of Monosodium Urate (MSU) crystals in joint tissues. With the global economic development and changes in dietary habits, the prevalence of GA has increased significantly, especially in the younger population. In order to deeply study the pathological mechanism of GA and the effect of drug therapy, it is particularly important to establish stable and reliable animal models. In this paper, we will introduce the establishment method and research progress of the model of gouty arthritis (GA).
Pathologic mechanism of gouty arthritis:
The pathological mechanism of GA mainly involves purine metabolism disorders, resulting in increased uric acid production or decreased excretion, which in turn causes elevated blood uric acid levels. When blood uric acid reaches saturation, sodium urate microcrystals will be deposited in the joint capsule, synovium, cartilage, bone and other joint tissues, triggering lesions and inflammatory reactions in the synovium and surrounding tissues.MSU crystals are recognized by the innate immune system as a foreign body through membrane receptors, inducing the production of various inflammatory chemokines and activating factors, thus activating both the innate and the innate immune system, and ultimately leading to the appearance of acute GA symptoms.

Classification of GA animal models and methods of establishment:
### 1. Acute GA model
Acute GA model is one of the most widely used models in GA research. The most commonly used modeling method is the direct injection of MSU crystal suspension into the joint cavity of experimental animals. This method was first proposed by Coderre et al. They successfully induced acute GA by injecting MSU crystal suspension into the joint cavity of male SD rats. This method has the advantages of stability, simplicity, and ease of operation, but it has the problems of limited dosage and the tendency to inject reagents subcutaneously or extracorporeally during puncture.
#### Specific operational steps:
1. Anesthetize the experimental animals (e.g. SD rats or New Zealand white rabbits) and fix them.
2. Disinfect the joints and inject the MSU crystal suspension into the joint cavity (e.g. ankle or knee joint) with a syringe.
3. Observe the swelling, redness and behavioral changes of the joints after injection.
4. The success of the model was further confirmed by pathological sections and biochemical tests.
### 2. Chronic GA and gout stone model
Chronic GA and gout stone model is mainly used to study the long-term development of GA and the formation mechanism of gout stone. A commonly used modeling method is to inject treated sterilized air subcutaneously into the animal to augment the area, and then inject MSU crystal suspension into the augmented area to simulate gouty nodular swelling and gouty stone formation. The model has the pathologic features of gouty synovitis, but cannot fully simulate the bone damage at the site of joint inflammation.
### 3. Hyperuricemic GA model
Hyperuricemia is an important biochemical basis of GA. In order to more comprehensively simulate the pathogenesis of GA, researchers often establish a hyperuricemia model by increasing the source of uric acid and decreasing the excretion of uric acid, and incorporate an acute GA model on this basis. Specific methods include feeding, gavage, intraperitoneal injection or subcutaneous injection of high-purine components or uricase inhibitors to induce a sustained increase in serum uric acid levels in animals.
Application and significance of the model:
GA animal model plays an important role in drug development, drug efficacy evaluation and pathological mechanism research. By comparing the effects of different drugs on the GA model, potential anti-gout drugs can be screened and their mechanisms of action can be explored in depth. In addition, the GA model also helps to reveal the pathophysiological process of GA and provides a theoretical basis for clinical treatment.
Summary and Prospect:
The establishment of the gouty arthritis (GA) model by InnoModels Biotechnology has provided an important tool for GA research. With the continuous progress of research technology, the method of GA model establishment has been improved to more accurately simulate the pathogenesis and pathological characteristics of GA. In the future, through further research and optimization, the GA model is expected to play a greater role in drug development, disease diagnosis and treatment, and bring benefits to gout patients.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd